董事會薪酬與考核委員會實施細則 第一章 總則 第二章 人員組成 1 Shanghai Longcheer Technology Co., Ltd. 上海龍旗科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9611） 第一條 為進一步建立健全上海龍旗科技股份有限公司（以下簡稱「公司」）董 事（非獨立董事）及高級管理人員的考核和薪酬管理制度，完善公司 治理結構，根據《中華人民共和國公司法》《上市公司治理準則》《上 海證券交易所股票上市規則》《上海證券交易所上市公司自律監管指 引第1號－規範運作》《香港聯合交易所有限公司證券上市規則》（以 下簡稱「《香港上市規則》」）等法律、行政法規和規範性文件、公司 股票上市地證券監管規則及《上海龍旗科技股份有限公司章程》（以 下簡稱「《公司章程》」）的有關規定，結合公司的實際情況，公司特 設立董事會薪酬與考核委員會，並制定本細則。 第二條 薪酬與考核委員會是董事會設立的專門工作機構，主要負責制定公 司董事及高級管理人員的考核標準並進行考核；負責制定、審查公 司董事及高級管理人員的薪酬政策與方案，對董事會負責。 第三條 本細則所稱高級管理人員是指董事會聘 ...

Shanghai Longcheer Technology Co., Ltd. （於中華人民共和國註冊成立的股份有限公司） 上海龍旗科技股份有限公司 （股份代號：9611） 董事會審計委員會實施細則 第一章 總則 1 第一條 上海龍旗科技股份有限公司（以下簡稱「公司」）為強化董事會決策功 能，做到事前審計、專業審計，確保董事會對經理層的有效監督， 進一步完善公司治理結構，根據《中華人民共和國公司法》（以下簡 稱「《公司法》」）、《上市公司治理準則》《上海證券交易所股票上市規 則》《上海證券交易所上市公司自律監管指引第1號 － 規範運作》、 《香港聯合交易所有限公司證券上市規則》（以下簡稱「《香港上市規 則》」）等法律、行政法規和規範性文件、公司股票上市地證券監管 規則以及《上海龍旗科技股份有限公司章程》（以下簡稱「《公司章 程》」）的有關規定，結合公司的實際情況，公司特設立董事會審計 委員會，並制定本細則。 第二條 審計委員會是董事會設立的專門工作機構，主要負責對公司內、外 部審計、內控體系進行監督、核查，對董事會負責，向董事會報告 工作，並行使《公司法》及公司股票上市地證券監管規則規定的監事 會的職權。 第 ...

上海龍旗科技股份有限公司 章 程 （H股發行並上市後適用） 二〇二六年一月 1 | 第一章 | 總 則 | | 4 | | --- | --- | --- | --- | | 第二章 | | 經營宗旨和範圍 | 5 | | 第三章 | 股 份 | | 6 | | | 第一節 | 股份發行 | 6 | | | 第二節 | 股份增減和回購 | 8 | | | 第三節 | 股份轉讓 | 10 | | 第四章 | | 股東和股東會 | 11 | | | 第一節 | 股東的一般規定 | 11 | | | 第二節 | 控股股東和實際控制人 | 14 | | | 第三節 | 股東會的一般規定 | 16 | | | 第四節 | 股東會的召集 | 19 | | | 第五節 | 股東會的提案與通知 | 21 | | | 第六節 | 股東會的召開 | 23 | | | 第七節 | 股東會的表決和決議 | 27 | | 第五章 | | 董事和董事會 | 32 | | | 第一節 | 董事的一般規定 | 32 | | | 第二節 | 董事會 | 36 | | | 第三節 | 獨立董事 | 47 | | | 第四節 | 董事會專門委員會 ...

Major Events - Mingming is busy (01768) plans to globally offer 14.1011 million H-shares from January 20 to January 23, introducing cornerstone investors such as Tencent [1] - Skyworth Group (00751) intends to privatize and delist while spinning off its solar business for listing, resuming trading on January 21 [1] - InnoCare Pharma (01672) has selected a new generation of monthly subcutaneous injection GLP-1R/GIPR/GCGR three-target agonist peptide ASC37 for clinical development [1] - Heartway Medical-B (06609) has had its registration application for a self-expanding intracranial drug-eluting stent accepted by the National Medical Products Administration [1] Project Investments - China Duty Free Group (01880) subsidiary plans to acquire all issued shares of DFS Cotai Limitada [2] - Jiutai Bonda Energy (02798) intends to increase investment of approximately 114 million yuan to acquire a 51% stake in Guizhou Huaneng Jiayuan Coal Industry Co., Ltd. [2] - Crystal International (02232) plans to acquire land in Egypt for 30.4 million USD [2] Share Buybacks - Kuaishou-W (01024) repurchased 393,000 shares for 29.9525 million HKD on January 20 [2] - Geely Automobile (00175) spent approximately 63.6286 million HKD to repurchase 3.788 million shares on January 20 [2] - Sunny Optical Technology (02382) repurchased 1.4 million shares for 88.6084 million HKD on January 20 [2] - Xiaomi Group-W (01810) repurchased 5.5 million shares for 196 million HKD on January 20 [2] Operating Performance - Zhaoyan New Drug (06127) expects to achieve a net profit attributable to shareholders of approximately 233 million to 349 million yuan in 2025, representing a year-on-year increase of about 214.0% to 371.0% [2] - China Longgong (03339) issued a profit warning, expecting a significant increase in annual net profit [2] - Heartway Medical-B (06609) anticipates revenue of approximately 400 million to 410 million yuan in 2025, a year-on-year increase of at least 43.9% [3] - Anta Sports (02020) expects low single-digit positive growth in retail sales for Anta brand products and mid-single-digit positive growth for FILA brand products in 2025 [3] - Anton Oilfield Services (03337) reported new orders of 2.084 billion yuan in the fourth quarter, a year-on-year decrease of 20% [3]

智通财经APP讯，龙旗科技(09611)发布公告，于2026年1月20日，发售价已厘定为每股H股31.00港元。 ...

格隆汇1月20日丨龙旗科技(09611.HK)发布公告，于2026年1月20日，发售价已厘定为每股H股31.00港 元。 假设全球发售于2026年1月22日(星期四)上午八时正(香港时间)或之前成为无条件，预期H股将于2026年 1月22日(星期四)上午九时正(香港时间)在联交所主板开始买卖。H股将以每手买卖单位100股H股买卖。 ...

除本公告另有界定者外，本公告所用詞彙與招股章程所界定者具有相同涵義。 香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表聲明，並明確表示概不 會就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公告不會直接或間接於或向美國（包括其領土及屬地、美國任何州以及哥倫比亞特區）發佈、 刊發或派發。本公告並不構成或組成在美國境內或於任何其他司法轄區購買或認購任何證券的 任何要約或招攬的一部分。發售股份並無亦不會根據《1933年美國證券法》（經修訂）（「美國證 券法」）或美國任何州或其他司法轄區的證券法登記。發售股份不得在美國境內提呈發售、出 售、質押或以其他方式轉讓，惟可獲豁免遵守美國證券法登記規定或毋須遵守美國證券法登記 規定的交易除外。發售股份不會在美國公開發售。發售股份僅可(1)根據美國證券法第144A條 或根據美國證券法的其他可用獲豁免登記向合資格機構買家（定義見第144A條）及(2)根據美國 證券法S規例在美國境外以離岸交易方式提呈發售及出售。 本公告僅作說明用途，並不構成收 ...

Group 1: IPO Market Overview - In the past week (January 12-18, 2026), a total of 29 companies submitted IPO applications in the Hong Kong market, including Qian Dama, Yuanji Food, and others [5][6] - Three companies passed the hearing at the Hong Kong Stock Exchange: Guoen Co., Dongpeng Beverage, and Muyuan Foods, all of which are already listed on A-shares [5][10] - Only one company, Longqi Technology, initiated its IPO process, with a global offering of 52.2591 million shares at a maximum price of HKD 31 per share [5][13] Group 2: Companies Going Public - Four companies officially listed on the Hong Kong Stock Exchange: Haowei Group, BBSB International, Zhaoyi Innovation, and Hongxing Cold Chain [5][14] - Yuanji Food is the largest Chinese and global Chinese fast-food enterprise, with a revenue of RMB 1.982 billion, up 11.0% year-on-year, and a net profit of RMB 142 million, up 18.8% [8][9] - Estun, a leading industrial robot company, reported a revenue of RMB 3.804 billion, up 12.9% year-on-year, and a net profit of RMB 25.372 million, recovering from a loss in the previous year [10][11] Group 3: Company Highlights - Guoen Co. focuses on chemical new materials and reported a revenue of RMB 17.444 billion, up 10.0% year-on-year, with a net profit of RMB 713 million, up 40.2% [11] - Muyuan Foods, a leader in the pork industry, achieved a revenue of RMB 111.79 billion, up 15.5% year-on-year, and a net profit of RMB 15.112 billion, up 34.4% [12] - Longqi Technology is a global leader in smart products and services, with its IPO set to launch on January 14, 2026, and expected to list on January 22, 2026 [13][14]

Core Viewpoint - The company, Shanghai Longcheer Technology Co., Ltd., is in the process of issuing H-shares and listing on the Hong Kong Stock Exchange, with significant steps already taken towards this goal [1][2][3][4][5] Group 1: Application and Approval Process - On June 27, 2025, the company submitted its application for H-share issuance to the Hong Kong Stock Exchange [1] - The China Securities Regulatory Commission confirmed the company's overseas issuance and listing on December 9, 2025 [1] - The Hong Kong Stock Exchange held a listing hearing on December 17, 2025, to review the company's application [2] Group 2: H-share Offering Details - The total number of H-shares for global offering is set at 52,259,100 shares, with 5,226,000 shares allocated for public offering in Hong Kong, representing 10% of the total [4] - The company can issue up to an additional 7,838,800 shares through an over-allotment option, bringing the maximum total to 60,097,900 shares if fully exercised [5] - The expected price for the H-shares is capped at HKD 31 per share, with the public offering starting on January 14, 2026, and ending on January 19, 2026 [5] Group 3: Listing Timeline - The H-shares are anticipated to be listed and commence trading on the Hong Kong Stock Exchange on January 22, 2026 [5]

Major Events - Longi Technology (09611) plans to globally offer 52.2591 million H-shares from January 14 to January 19 [1] - CK Life Sciences (00013) announced the results of the SACHI III study published in The Lancet [1] - Dongyang Sunshine Pharmaceutical (06887) launched an AI-driven R&D platform targeting the PROTAC mechanism, continuing to deepen its AI strategic layout [1] - Dongyao Pharmaceutical-B (01875) received a cash offer from WuXi AppTec (02268) at a premium of approximately 99%, with resumption of trading on January 15 [1] - Valiant Pharmaceuticals-B (09887) received Fast Track designation from the US FDA for its bispecific antibody, Opalizumab (LBL-024) [1] - Xunqi (03317) entered into a strategic cooperation framework agreement with Jinyong Investment to support digital transformation in investment research, trading, and risk management [1] Operating Performance - CITIC Securities (06030) reported a net profit attributable to shareholders of 30.051 billion yuan for 2025, an increase of 38.46% year-on-year [1] - CITIC Bank (00998) reported a net profit attributable to shareholders of 70.618 billion yuan for 2025, a year-on-year increase of 2.98% [1] - China General Nuclear Power New Energy (01811) completed a cumulative power generation of 19,000 GWh in 2025, a decrease of 0.8% year-on-year [1] - Yuexiu Property (00123) reported a cumulative contract sales amount of approximately 106.21 billion yuan for 2025 [1] - WuXi AppTec (02268) issued a profit warning, expecting a net profit growth of over 38% year-on-year for 2025 [1] - Jinyu Group (02009) issued a profit warning, anticipating a net loss attributable to shareholders of 900 million to 1.2 billion yuan for 2025 [1] - Saijing Technology (00580) issued a profit alert, expecting a net profit increase of approximately 30.0% for 2025 [1] - Beijing Beichen Industrial Co., Ltd. (00588) issued a profit warning, expecting a net loss attributable to shareholders of 2.696 billion to 3.38 billion yuan for 2025 [1]